Walter Greenblatt brings to our clients a vast store of business experience—both as an operating executive and an advisor to top management, of clients ranging from Fortune 500 companies to publicly-traded and privately-held mid-sized corporations.
After earning his MBA with Distinction from Harvard in 1982, he worked at Bain & Company, a leading strategy consulting firm. His projects included strategic planning, mergers & acquisitions, strategic cost analysis and marketing. He served clients in industries ranging from health care to financial services to manufacturing (including steel and oil industries).
An experienced entrepreneur and “hands-on” operating executive, Mr. Greenblatt founded and grew a profitable business, ultimately managing over 130 employees. He successfully sold the business after operating it for ten years.
His subsequent investment banking experience has focused on middle-market transactions. He has helped clients in a variety of healthcare and manufacturing industries to plan strategy, raise capital to implement the strategy and acquire and/or divest the business units necessary to achieve key goals.
Mr. Greenblatt received his MBA with Distinction from Harvard Business School in 1982. Previously he graduated summa cum laude from Yale and received a Masters degree in Economics with First Class Honors from Oxford University
Ezra Angrist has more than 15 years of experience in investment banking and business valuation.
His career began at the Westheimer Company, a boutique investment bank focused on special situation merger and acquisition advisory assignments. He subsequently joined Management Planning, Inc. (MPI), a leading national business valuation firm as a valuation analyst. After relocating to upstate New York he joined Paradigm Capital as an equity analyst covering a universe of high technology stocks for its hedge fund team.
Mr. Angrist initially joined Walter Greenblatt & Associates in 2003 as Director of Research. His assignments included financial modeling and identifying potential investors for clients. He was also chief compliance officer, responsible for handling WG&A's interactions with various regulators.
In 2007, he returned to MPI. His assignments included valuations of a variety of privately held life science companies as well as numerous companies from a range of industries including asset management, high technology and construction. During his time at MPI he also worked on investment banking assignments at MPI Securities, Inc., a FINRA-registered broker dealer and affiliate of MPI.
In 2013, he was pleased to return to WG&A as Vice President. His responsibilities include those mentioned above as well as reviewing prospective clients and strategic planning.
Mr. Angrist received his MBA from Rutgers University. He has also earned a Master's Degree in Politics (with a concentration in quantitative methods) from Princeton University. He graduated from Oberlin College with High Honors in Economics.
Ira Wallace, MD, MBA applies over 20 years of experience as a startup founder, life science investor and medical practitioner to his work with clients. Having founded, funded and brought a startup through FDA clearance, CE mark and the initiation of a new billing code he knows what it takes to help a young life science company to succeed.
During his career Ira has been consulted on marketing, clinical applications and new venture formation for a number of companies including Sharplan, Coherent, ESC and Sarnoff.
Ira has spent the past 11 years helping dozens of startup and development phase companies to grow and exit as an angel investor, strategy consultant and M&A advisor. He is an active member of the Angel Capital Association (ACA) and is a member of the ACA Life Science Syndication Committee.
Ira received his MBA from Columbia University Business School and is a member of the Beta Gamma Sigma honor society. He is a board certified ophthalmologist having completed a residency and a glaucoma research fellowship at the University of Pennsylvania.
Mark Eisenach has more than 20 years of corporate development, strategy, and executive management experience, primarily in the life sciences and high technology industries.
He is currently founder and Managing Director of Ridgeview Partners LLC, a Princeton, N.J.-based corporate advisory firm, and previously served as CEO of pharmaceutical services company Acurian Inc. Prior to that, he held a variety of senior executive positions at Covance Inc., one of the world's largest and most comprehensive drug development services companies. In these roles, he led Covance's worldwide business strategy, mergers and acquisitions, business partnerships and global marketing efforts, serving on the company's Global Leadership Council.
Earlier in his career, Mr. Eisenach spent eight years at the Boston Consulting Group and was a tax economist at Price Waterhouse. He received his AB from Harvard College and his MBA from Harvard Business School. He also holds Series 82 and Series 63 security licenses with Walter Greenblatt & Associates, Ridgeview Partners' investment banking partner.